scoliosis treatment market 2018-2027: Growth Opportunities, Current and Projected Market Size, Recent Industry Trends and Developments
Market Highlights
It is estimated that the global scoliosis treatment market is expected to register a CAGR of~ 3.9% during the forecast period of 2019 to 2025, with a market value of USD 2,580.2 million in 2018. Scoliosis causes the spine to curve to one side and can affect any part of the spine, but the most commonly affected areas are at the level of the chest and the lower back. The scoliosis treatment market is driven by various factors such as the increasing prevalence of scoliosis surgeries, increasing demand for spine surgeries, the high adoption rate of braces, and the growing prevalence of musculoskeletal disorders. However, the high cost of treatment or procedures and limited understanding of the disorder and available treatment options are expected to curb the growth of the scoliosis treatment market. The global scoliosis treatment market is currently dominated by numerous market players. The key players are involved in product launches and strategic collaborations to strengthen its market position. For instance, in July 2018, NuVasive Launched MAGEC X for early-onset scoliosis treatment. The latest advancement of MAGEC delivers improved rod strength together with internal rod mechanism advancements.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/8230
Regional Analysis
Based on region, the market can be divided into the Americas, Europe, Asia-Pacific, and the Middle East Africa. The scoliosis treatment market in the Americas has further been segmented into Latin America and North America, with the North American market further sub-segmented into the US and Canada. The European scoliosis treatment market has been sub-divided Western Europe and Eastern Europe. Western Europe has further been divided as France, Germany, the UK, Spain, Italy, and the rest of Western Europe. The scoliosis treatment market in Asia-Pacific has been bifurcated into Australia, China, Japan, India, South Korea, and the rest of Asia-Pacific. The scoliosis treatment market in the Middle East Africa has been segmented into the Middle East and Africa.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/scoliosis-treatment-market-8230
Segmentation
The global scoliosis treatment market has been segmented based on disease, product and distribution channel. The market, based on disease, has been further divided into infantile idiopathic scoliosis and adolescent idiopathic scoliosis. The adolescent idiopathic scoliosis segment is likely to hold a major share in the market due to the increasing prevalence of scoliosis in the adults majorly. The product segment has been segmented into cervical thoracic lumbar sacral orthosis (CTLSO), thoracolumbosacral orthosis (TLSO), and lumbosacral orthosis (LSO). The cervical thoracic lumbar sacral orthosis (CTLSO) is predicted to be the fastest-growing due to increasing demand for spine surgeries. The distribution channel segment has been categorized as hospitals clinics, retail pharmacies, and online pharmacies.
Key Players
Some of the key players in the global scoliosis treatment market are NuVasive, Spinal Technology, Inc., C H Martin Company, Aspen Medical Products, Lawall Prosthetics and Orthotics, SPINEFORM LLC, Össur, Orthotech, Chaneco, Boston Orthotics Prosthetics, Charleston Bending Brace, Trulife, DJO, Wilmington Orthotics Prosthetics, Inc., Horton’s Orthotics Prosthetics, UNYQ, Optec USA, Inc., and Zimmer Biomet Holdings Inc.
nasal drug delivery market 2027: In-Depth Analysis on Market Dynamics, Segmentation & Emerging Growth Factors
Market Synopsis:
The report published by Market Research Future (MRFR) states that the Middle East and Africa nasal drug delivery market is marked to exhibit noteworthy expansion at a CAGR of 8.1% during the forecast period of 2015-2022 and reach the market valuation of USD 1.59 Bn by the end of the assessment period form USD 1 Bn in the year 2015. Rapid development in the medical field and pharmaceutical industry is leading to the introduction of highly effective and innovative modes of drug administration systems for treating various medical conditions. Nasal drug delivery system is utilized for the treatment of local infections such as allergies, sinusitis, rhinitis, and others in the nasal course or paranasal sinuses. High prevalence of viral infections that causes blockage of the nasal cavity and respiratory disorders are inducing high demand for advanced treatment in the global market, leading to the expansion of the Middle East and Africa nasal drug delivery market. Increased availability of treatment solutions and proliferation in government initiative to provide treatment in the remote areas due to high unmet medical needs of the population in these areas are also propelling the growth of the Middle East and Africa nasal drug delivery market during the assessment period.
Segmental Analysis:
The Middle East and Africa nasal drug delivery market is segmented on the basis of dosage form, system, delivery technology, and therapeutic applications. Based on dosage form, the Middle East and Africa nasal drug delivery market has been segmented into drops, sprays, powder, gels, and ointments. Based on system, the Middle East and Africa nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose. Based on delivery technologies, the Middle East and Africa nasal drug delivery market has been segmented into spray, nebulizers and other. Based on therapeutic applications, the Middle East and Africa nasal drug delivery market has been segmented into rhinitis, congestion, vaccinations and others.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/2696
Regional Analysis:
Geographically, the Middle East and Africa nasal drug delivery market has been segmented into six major countries such as the UAE, Egypt, Saudi Arabia, Kuwait, Qatar, and Oman. Among these, the nasal drug delivery market in the UAE commands the major share of the Middle East and Africa nasal drug delivery market owing to the presence of well-developed healthcare infrastructure, high healthcare expenditure by the population of this area, increasing availability of vaccinations and other treatment options and high demand for advanced mode of drug administration in this country. Egypt commands the second largest share of the Middle East and Africa nasal drug delivery market owing to the increasing awareness regarding the availability of treatments for nasal infections, presence of developed healthcare sector as this country attracts a large number of international tourists who require proper healthcare and proliferation in government initiative to provide optimum healthcare solutions in this country. Low penetration of healthcare facilities and lack of awareness in the remote areas of the Africa region are leading to the slow growth of the nasal drug delivery market in this region. However, increased government support for providing healthcare facilities in such areas due to high unmet medical needs of the population is contributing to the expansion of the nasal drug delivery market in this region.
Access Report @ https://www.marketresearchfuture.com/reports/nasal-drug-delivery-market-2696
Competitive Analysis:
Some of the major players profiled by Market Research Future (MRFR) that are operating in the global drug delivery market are Novartis AG, Pfizer, Inc., Sanofi-Aventis, GlaxoSmithKline Plc, Merck Co., Inc., AptarGroup Inc., Johnson Johnson Services, Inc., Becton Dickson Company and others. The players in the Middle East and Africa nasal drug delivery market are focusing on the expansion of their business on a global level by increasing research expenditure for the development of advanced treatment solution and innovative modes of drug administration. Initiatives such as strategically planned mergers and acquisitions are aiding the players to sustain the competition and retain their dominance over the Middle East and Africa nasal drug delivery market during the assessment period.
biomarker test market to Register Steady Growth During 2017 to 2027
Biomarker Test Market – Overview
The biomarker test market is growing mainly due to rising prevalence of genetic disorders. According to a recent study report published by the Market Research Future, the biomarker test market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).
Most healthcare professionals use diagnosis tests to clarify and support their clinical decision making. Progressively over recent years, the analytic procedure has turned out to be stronger by the need to preselect patients in light of medications and licenses. This move has come to through various factors, which incorporate propelling technology (empowering professionals to measure more particular markers of adequacy), an increased comprehension of the disease procedure, and a more prominent energy about the uniqueness of an individual’s tumour at the molecular level. Biomarkers on drug labels are improving the focus on biomarker testing by the administrative sector which is highlighted by the developing number of medications with this information on their labels.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/3570
Notably, demand for biomarkers in various technologies such as next-generation sequencing (NGS) technologies, and ultra-high throughput sequencing is the primary driver for biomarker test market. The software and hardware are the technological building blocks of biomarkers tests. The changes in emerging technologies are affecting various initiatives like, the shift to companion diagnostics, NGS and many others. Evolutions of targeted therapies, more research and development programs are supporting this trend as it has enormous potential for more Biomarker Test offerings in undeveloped countries.
Other push factors such as, growing prevalence of genetic diseases, growing potential of biomarkers in targeted therapies, involvement of patients in personal healthcare, and rising healthcare expenditure are also fuelling the growth of the market. Among all disease categories, recent advances in cancer care have been most closely associated with genomic medicine. Understanding the genetic mutations of individual tumour’s holds the promise of giving physicians greater capacity to prescribe specific medicines to fight specific cancer types. But there are only a few cancers and cancer types that have been associated with specific genetic mutations.
Despite these drivers, lack of awareness about the possible applications of biomarkers, regulatory framework, and lack of research and indications creating difficulties in the application are expected to hinder the growth of the market. The challenges in adopting personalized medicine are boundless. The first and foremost challenge affecting the biomarker tests landscape is coordinating the timelines. Aligning the development of a drug and diagnostic design program requires a lot of careful planning.
Access Complete Report @ https://www.marketresearchfuture.com/reports/biomarker-test-market-3570
Biomarker Test Market – Competitive Analysis
The Biomarker Test market is currently dominated by various players. Due to rising research and development expenditure various existing and new marketers are continuously coming up with advanced products to control genetic, and other complications. The global biomarker test market is currently dominated by numerous players.
Roche is one of them by holding a strong share in the market. Roche is the world’s biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The company offers various products in the pharmaceutical, diagnostics and research industry such as ACCU-CHEK Safe-T-Pro lancet, Accu-Chek Multiclix Finger Pricker, Accu-Chek FastClix, Accu-Chek Softclix, and others. In February, 2015, Roche acquired Signature Diagnostics AG (Signature), a privately held company based in Potsdam, Germany. In the same year, Roche got an approval from FDA for Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema.
Novartis AG is another renowned market player in biomarker test market. The product portfolio of company includes Biosimilar’s, oncology injectable, anti-invectives, targeted therapy, cell gene therapy, and others. In March, 2016, Novartis cancer drug gets FDA’s principal ‘biosimilar’ affirmation. Federal regulators have permitted the first “biosimilar” drug to be sold in the U.S. under a program intended to branch a new market of lower-cost substitutes to some of the most expensive treatments in healthcare. This approval of biosimilars will help many patients who are in need of these treatments.
Medical Implant Market Size – Rising New Technologies Research Forecast to 2027
Market Highlights
Global Medical Implant Market is expected to have a market value of USD 279,418.06 Million by 2027.
Medical implants are devices that are placed inside or on the surface of the patient body. Many implants are prosthetics envisioned to replace missing body parts. Other implants deliver medication, provide support to organs and tissues or monitor body functions. Due to the improvement in surgical outcomes, the increasing prevalence of chronic disease has boosted the demand for medical implants, thereby accelerating market growth. The Increasing geriatric population is anticipated to drive the demand for medical implants further.
Segment Analysis
Global Medical Implant Market has been segmented into Type, Type of Material, and End User. The global medical implant market, by type, has been segmented into orthopedic implants, cardiac implants, spinal implants, dental implants, ophthalmic implants, cosmetic implants, others. On the basis of type of material, the market is bifurcated into metallic material, ceramic material, polymers material, others. On the basis of end user, the market is categorized into hospitals clinics, research laboratories, and others.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/2806
Regional Analysis
Global Medical Implant Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. Americas accounted for the largest market share in 2019. This can be attributed to the high prevalence of chronic diseases, product launches, and technological advancement in this region. The high demand for medical implants and the adequate availability of skilled professionals in the region are expected to fuel the regional market growth. According to a SelectUSA.gov publication, the US has the largest medical device market in the world. Additionally, the growing elderly population is also helping in the growth of the medical implant market in the Americas. As per the Administration for Community Living, in the Americas, over the last ten years, the population aged 65 and over grew from 37.2 million in 2006 to 49.2 million in 2016.
The European medical implant market has been divided into Western Europe and Eastern Europe. The Western Europe medical implant market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe is estimated to hold the second position in the medical implants market in 2019. A large patient pool, an increasing number of orthopedic surgeries, and availability of advanced products in the region are some of the key factors attributing to the market growth. In 2017, Switzerland, Finland, Luxembourg, Germany, Austria, and Belgium were the countries with the highest number of hip and knee replacements in the region. The OECD averages are 135 per 100,000 for knee replacements and 182 per 100,000 population for hip replacements. Since 2000, the hip and knee replacement procedures have increased rapidly in most OECD countries.
The medical implant market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to register the highest market growth potential over the forecast period due to the booming geriatric population. According to the United Nations, the number of people aged 65 and above is expected to grow dramatically over the next 50 years across Asia. The population in this age group will increase by 314%, from 207 million in 2000 to 857 million in 2050. Moreover, increasing per capita disposable income of middle-class families, which accounts for a large population in Asia, results in individuals spending more on health. This is one of the factors driving the growth of the regional medical implant market during the study period.
The Middle East Africa medical implant market is segmented into the Middle East and Africa. The key factors propelling the growth of the regional market are increasing in the number of rises in the prevalence of cardiac and orthopedics disorders and funding by private players and government bodies. As per a report by the International Trade Administration, the Saudi health care sector is the largest in the Near East. Saudi Arabia’s health and social affairs budget for 2019 outlines an 8% increase to USD 46 billion compared to USD 42.4 Billion in 2018.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/medical-implants-market-2806
Key Players
MRFR recognizes the following companies as the Key Players in the Global Medical Implant Market— Boston Scientific Corporation (US), Johnson Johnson (US), Stryker Corporation (US), 3M (US), and Zimmer Biomet (US).
Key Findings of the Study
Market Highlights
Global Medical Implant Market is expected to have a market value of USD 279,418.06 Million by 2027.
Medical implants are devices that are placed inside or on the surface of the patient body. Many implants are prosthetics envisioned to replace missing body parts. Other implants deliver medication, provide support to organs and tissues or monitor body functions. Due to the improvement in surgical outcomes, the increasing prevalence of chronic disease has boosted the demand for medical implants, thereby accelerating market growth. The Increasing geriatric population is anticipated to drive the demand for medical implants further.
Segment Analysis
Global Medical Implant Market has been segmented into Type, Type of Material, and End User. The global medical implant market, by type, has been segmented into orthopedic implants, cardiac implants, spinal implants, dental implants, ophthalmic implants, cosmetic implants, others. On the basis of type of material, the market is bifurcated into metallic material, ceramic material, polymers material, others. On the basis of end user, the market is categorized into hospitals clinics, research laboratories, and others.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/2806
Regional Analysis
Global Medical Implant Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. Americas accounted for the largest market share in 2019. This can be attributed to the high prevalence of chronic diseases, product launches, and technological advancement in this region. The high demand for medical implants and the adequate availability of skilled professionals in the region are expected to fuel the regional market growth. According to a SelectUSA.gov publication, the US has the largest medical device market in the world. Additionally, the growing elderly population is also helping in the growth of the medical implant market in the Americas. As per the Administration for Community Living, in the Americas, over the last ten years, the population aged 65 and over grew from 37.2 million in 2006 to 49.2 million in 2016.
The European medical implant market has been divided into Western Europe and Eastern Europe. The Western Europe medical implant market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe is estimated to hold the second position in the medical implants market in 2019. A large patient pool, an increasing number of orthopedic surgeries, and availability of advanced products in the region are some of the key factors attributing to the market growth. In 2017, Switzerland, Finland, Luxembourg, Germany, Austria, and Belgium were the countries with the highest number of hip and knee replacements in the region. The OECD averages are 135 per 100,000 for knee replacements and 182 per 100,000 population for hip replacements. Since 2000, the hip and knee replacement procedures have increased rapidly in most OECD countries.
The medical implant market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to register the highest market growth potential over the forecast period due to the booming geriatric population. According to the United Nations, the number of people aged 65 and above is expected to grow dramatically over the next 50 years across Asia. The population in this age group will increase by 314%, from 207 million in 2000 to 857 million in 2050. Moreover, increasing per capita disposable income of middle-class families, which accounts for a large population in Asia, results in individuals spending more on health. This is one of the factors driving the growth of the regional medical implant market during the study period.
The Middle East Africa medical implant market is segmented into the Middle East and Africa. The key factors propelling the growth of the regional market are increasing in the number of rises in the prevalence of cardiac and orthopedics disorders and funding by private players and government bodies. As per a report by the International Trade Administration, the Saudi health care sector is the largest in the Near East. Saudi Arabia’s health and social affairs budget for 2019 outlines an 8% increase to USD 46 billion compared to USD 42.4 Billion in 2018.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/medical-implants-market-2806
Key Players
MRFR recognizes the following companies as the Key Players in the Global Medical Implant Market— Boston Scientific Corporation (US), Johnson Johnson (US), Stryker Corporation (US), 3M (US), and Zimmer Biomet (US).
Key Findings of the Study
- Global Medical Implant Market is estimated to reach USD 279,418.06 Million by 2027 at a CAGR of 7.60% during the assessment period of 2020 to 2027
- The Americas accounted for the largest share of the global medical implant market due to the increasing number of medical implant procedure, rising cases of chronic diseases, and technological advancement.
- Based on type, the orthopedic implants segment accounted for the largest market share of 38.8% in 2019.
- Based on type of material, the market is segmented into metallic material, ceramic material, polymers material, and others. The resin composites segment dominated the market in the year 2019 and is anticipated to grow at a CAGR of 8.07% during the forecast period.
- Based on end user, the hospitals clinics segment dominated the market in 2019.
- Global Medical Implant Market is estimated to reach USD 279,418.06 Million by 2027 at a CAGR of 7.60% during the assessment period of 2020 to 2027
- The Americas accounted for the largest share of the global medical implant market due to the increasing number of medical implant procedure, rising cases of chronic diseases, and technological advancement.
- Based on type, the orthopedic implants segment accounted for the largest market share of 38.8% in 2019.
- Based on type of material, the market is segmented into metallic material, ceramic material, polymers material, and others. The resin composites segment dominated the market in the year 2019 and is anticipated to grow at a CAGR of 8.07% during the forecast period.
- Based on end user, the hospitals clinics segment dominated the market in 2019.
global oligonucleotide pool market to Witness Increase in Revenues by 2027
Global Oligonucleotide Pool Market – Overview
It has been noted that global oligonucleotide pool market is growing at moderate pace and is expected to grow at the CAGR of 8.5%. Oligonucleotide pool market is driven by three major factors such as huge investments from big pharmaceutical companies in oligonucleotide therapeutics for drug development, CMO’s involvement in manufacturing therapeutic oligonucleotides and wide application areas offered by the oligonucleotides.
There are only small number of approved oligonucleotide drugs available in the market. Currently there are only three drugs available in the U.S. Having said that, according to Nitto Denko Avecia internal research, nearly 116 oligonucleotides were in active clinical trials as of August 2015. Very few of the oligonucleotide drug sponsors have their own in-house cGMP manufacturing facilities. On the other hand, more than half of the oligonucleotides in the clinical development stage are manufactured by the contract manufacturing organizations (CMO). As more number of oligonucleotides are on the verge of regulatory approval, the demand for such oligonucleotides will increase in the market. The increased demand is likely to force the CMO’s to increase their capacity and improve efficiency in manufacturing the oligonucleotides. CMO’s are adopting different strategies to increase the manufacturing capacity. For example, in 2014, German CMO BioSpring added a midscale synthesizer to increase the capacity. Nitto Denko Avecia, the leading CMO has implemented the use of thin film evaporation in order to concentrate product solutions prior to lyophilisation which results in larger final batches of custom oligos. The increasing involvement of the CMOs in order to cater to the demand of oligonucleotides is likely to boost the growth of the oligonucleotide pool market.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/2556
Global Oligonucleotide Pool Market – Competitive Analysis
February, 2017 – Integrated DNA Technologies, Inc. had announced the acquisition of oligo manufacturing business of GeneWorks (Australia). This acquisition by the company enhances the capacity for direct sales of genomic products in Asia-Pacific region. Integrated DNA Technologies, Inc. (IDT) is one of the leading biotechnology company that is involved in manufacturing, developing nucleic acid products for the life sciences industry. The company mainly sells and distributes short strands of DNA called oligonucleotides. The company’s essential business is the creation of custom oligonucleotides for molecular biology applications. IDT has created restrictive innovations for genomics applications, which include generation sequencing, CRISPR genome editing, qPCR, and RNA interference. The products offered by the company serves many of the small university academic research, biotechnology, clinical diagnostics, and pharmaceutical development all around the world. The company is specialized in Custom Oligonucleotides, DNA Synthesis, Synthetic Biology, RNA Synthesis, Synthesis Reagents, Next generation sequencing, Nucleic Acid Synthesis, Genes gene fragments, Primers, GMP Manufacturing, Genotyping, Probes, RNAi, qPCR, and CRISPR genome editing.
December, 2016 – Agilent Company announced the acquisition of Multiplicom N.V., a Leading European Diagnostics Company. On this acquisition Herman Verrelst, vice president said “The acquisition of Multiplicom significantly strengthens our presence in the genomics market”. Agilent is one of the leaders in life sciences, diagnostics and applied chemical markets. The company provides services to laboratories all around the world with its instruments, services, consumables, applications and expertise. Agilent mainly focuses on six major industries which involve food, environmental and forensics, pharmaceutical, diagnostics, chemical and energy and research. The company with its three brands CrossLab combines, Dako Agilent Pathology Solutions and Agilent OpenLAB Software Suite is innovating and providing special services to laboratories with high technology.
Report Details @ https://www.marketresearchfuture.com/reports/oligonucleotide-pool-market-2556
Global Oligonucleotide Pool Market – Regional Analysis
As per Market Research Future analysis, the global oligonucleotide pool market has grown tremendously in Asia-Pacific. Geographically, North America holds the largest share of more than 42.2% of oligonucleotide pool market and is expected to be the leading market during 2016-2022. The major factor that influences the growth of the North American oligonucleotide pool market is the existence of large number of small scale and big scale manufacturers of oligonucleotide pool and service providers in the region.
After North America region, Europe market is the second largest market in the global oligonucleotide pool market. Increasing investment by organizations in the field of genomics serves as a significant driver for this region. Whereas Asia Pacific region is expected to be the fastest growing market due to increasing RD funding by the developing countries like China and India for the development of oligonucleotide products.
global anal fissure treatment market size by Industry Insight Analysis, Segments, Top Key Players, Drivers and Trends to 2027
The global anal fissure treatment market is expected to rise and touch a valuation of USD 2,526.5 million by 2023, at a 7.6% CAGR during the forecast period (2018-2023). Anal fissures are small tears near the mucosal lining of the anus. Deeper cuts may take a combination of oral and topical medicine to alleviate the pain.
The anal fissure treatment market is expected to thrive owing to the booming pediatric and geriatric patient pool. Advances in technology coupled with various treatment options is likely to lead to a windfall for the market over the forecast period. High incidence of constipation is predicted to drive the need for anal fissure treatments. This is backed by vulnerability of the elderly which find it difficult to pass stools properly. According to the American Gastroenterological, nearly 33% of Americans above 60 experience the condition.
Unhealthy lifestyles adopted by patients is likely to cause the condition and boost the market demand. Popularity of over-the-counter (OTC) drugs may spur the market growth owing to need for rapid treatment options. Drug manufacturers have shifted their focus to developing economies which offer lucrative growth avenues.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/3841
Segmentation:
The anal fissure treatment market is segmented by treatment type, route of administration, and end-user.
By treatment type, oral held 78.3% share of the anal fissure treatment market in 2017, followed by topical (16%) and others (5.7%). Oral segment had a valuation of USD 1,284.1 million in 2017 and inflate to USD 2,004.2 million by 2023. Oral medicines include calcium channel blockers and pain-relieving agents such as Tribenzo and LOMOTIL drugs. On the other hand, topical medications can generate close to USD 405.8 million by 2023 at a CAGR of 7.7% during the assessment period.
By route of administration, medications held close to 86.1% share of the market in 2017, followed by surgery (13.9%). Surgery has a high success rate compared to other forms of medical therapy but are considered expensive. This segment can exhibit 6.9% CAGR over the assessment period to attain a value of USD 339.5 million by 2023. On the other hand, medications can generate close to USD 2,186.9 million by 2023 at a CAGR of 7.7% during the forecast period. This can be attributed to various topical or oral medications proposed to patients as alternatives to surgery.
By end-user, hospitals clinics held the largest market share in 2017 owing to the growing patient visits for anal fissure treatments. Improved healthcare facilities in developing countries are likely to balloon the segment valuation to USD 1,717.1 million by 2023. Research academic institutes can exhibit a 7.7% CAGR during the forecast period to generate close to USD 617.6 million by 2023.
Regional Analysis:
Region-wise, the anal fissure treatment market includes Americas, Europe, Asia Pacific (APAC), and Rest-of-the-World (RoW).
Americas accounted for 39.1% market share in 2017, followed by Europe (26.7%) and APAC (20%). The Americas are predicted to touch a valuation of USD 1,000.6 million by 2023 at a CAGR of 7.8% over the forecast period. This can be credited to rising number of cases of inflammatory bowel disease among the American populace.
The Europe anal fissure treatment market is likely to attain close to USD 678.1 million by 2023. This can be credited to sedentary lifestyles and improper eating habits of residents in the region. In addition, cases of chronic constipation and food allergies among children can elicit market demand.
The APAC region is projected to register 7.9% CAGR during the forecast period. This can be attributed to new product launches by pharmaceutical and biotechnology companies. The region can touch a size of USD 513.9 million by 2023.
Competitive Analysis:
Major names operational in the anal fissure treatment market are AstraZeneca (U.K.), Abbott Laboratories (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Eisai Co. Ltd. (Japan), Cigna (U.S.), Bayer AG (Germany), Taro Pharmaceutical Industries Ltd. (Israel), Allergan Inc. (U.S.), Valeant Pharmaceuticals International Inc (Canada), Teva Pharmaceutical Industries Ltd. (Israel), and Cook (U.S.).
Report Details @ https://www.marketresearchfuture.com/reports/anal-fissure-treatment-market-3841
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans conducts meet with the industry experts and industrial visits for its research analyst members.
Global Veterinary CBD Market : Latest Trends, Demand and Analysis 2027
Market Overview
The Global Veterinary CBD Market is poised to register a CAGR of 129.97% during the forecast period.
This impressive CAGR is possible due to the increasing number of household pets, the rising demand for humane practices in livestock management, and the easing of restrictions governing the use of CBD products to treat various ailments.
The market for global veterinary CBD products is already very diverse with multiple channels of sale.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/8138
SEGMENTATION
By Source
CBD products are derived from two principle sources. Each source produces its own strain and strength of CBD-related products and independently rank within the legal framework of nations.
- Marijuana-Derived: Marijuana is prized for its potent THC production but is hampered by the lack of a supporting legal framework for manufacture and processing. This is changing rapidly with marijuana being legalized in countries such as Canada and South Africa and various states in the US. Many countries are moving toward legalization the growth and sale of marijuana and are, therefore, potential markets for CBD products in the foreseeable future.
- Hemp-Derived: Hemp has been traditionally valued for the strength of its fiber which is used in numerous industries. With the advent of CBD products and the laws restricting marijuana production, hemp is being used as a source of THC for the production of numerous CBD items. Though it has a weaker THC count than marijuana, hemp is legal throughout the world, resulting in the larger market share for the segment.
By Product
There is a vast array of veterinary CBD products available in the market.
- Food-Grade: Leading the market for global veterinary CBD products are food-grade items. This can be attributed to the increasing spending by pet owners. The US pet food market is expected to grow by 4.5% from 2018 to 2019, while the pet healthcare market is projected to reach USD 18.98 billion by 2019, growing by 4.8% from the previous year. The segment can be further divided into:
- Treats: Ideal for small doses and inducing calmness
- Chews: Best for animals that tend to gnaw
- Others: Items such as hemp capsules and hemp biscuits
- Therapeutic-Grade: Though the certification process for therapeutic products for animals is lengthy, the easing of restrictions on CBD products for medicinal purposes shall ensure that the segment registers the highest growth rate.
- Pet Supplements: CBD-infused pet supplements is a growing market increasing research on the beneficial effects of CBD in treating various mental and physiological pet afflictions.
- Pet CBD Oils: Used for a plethora of ailments
- Personal Care: These products focus on the mental health of animals, an area which has seen remarkable growth in recent years.
By Distribution Channel
The growth of the global veterinary CBD market is directly impacted by the distribution channels. The distinguishable channels are:
- E-Commerce: Top distribution channel for this market, it is expected to as long as THC manufacture and processing remain in the legal gray area globally.
- Retail Pharmacies: The primary distribution point for CBD products for household pets, with an edge over the livestock CBD market.
- Veterinary Clinics: The primary distribution point for the global livestock CBD market, this segment is expected to register the highest growth rate as veterinary CBD products find greater acceptance.
- Others: Direct distribution from the manufacturer and mass orders for large-scale livestock farms are covered in this segment.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/veterinary-cbd-market-8138
Key Players
- Honest Paws (US)
- HolistaPet (US)
- HempMy Pet (US)
- Canna-Pet (US)
- Joy Organics (US)
- Fomo Bones (US)
- Pet Releaf (US)
- Green Roads of Florida (US)
- Wet Noses (US)
By Region
The global veterinary CBD market is currently concentrated in North America but there is significant untapped potential in other regions due to the increasing number of pets with a corresponding rise in spending on pets.
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East Africa
- Middle East
- Africa
CAR T-Cell Therapy Market Covering Competitive Scenario & Market Dynamics throughout 2027
Market Drivers and Restraints
Market Research Future (MRFR) analysed the global CAR T-Cell Therapy Market 2020a across the review period till 2023. As per MRFR assessment, the Global CAR T-Cell Therapy Market can thrive at 58.52% CAGR across the analysis period. By 2025, the global CAR T-Cell Therapy market value can rise at USD 8716.06 Million by 2025. The growing preference for Chimeric Antigen Receptor (CAR) T Cell Therapy as cancer treatment among the rising number of patients can support the expansion of the market. The immunotherapy therapy uses T cells to treat patient that offers high recovery rate and greater safety. Thus the increase in the adoption of CAR T-Cell therapy can promote the market in the near future. The rise in prevalence of cancer, rapid technological advancements, the rise in awareness about the greater reliance of the treatment, and expansion of the global pharmaceutical industry can cause the CAR T-cell therapy market gain momentum. Increase in clinical studies can also work in favor of the worldwide CAR T cell therapy market. On the contrary, expensiveness and rise in awareness about side-effects of CAR T-cell therapy can hinder the market rise.
Market Segmentation
The segment assessment of the global CAR T cell therapy market is done by target antigen and application. The type-based segments of the CAR T cell therapy market are CD22, and CD19 among others. The CD19 target antigen segment can earn revenue of above USD 342.56 Mn by 2025. The application-based segments of the global CAR T cell therapy market are diffuse large B-cell lymphoma, and acute lymphoblastic leukemia among others.
The growing geriatric population with weak immune system are highly prone to several malaises. Thus, the increase in need for CAR-T cell therapy among geriatric cancer patients can favor the market expansion across the review period. In addition, the growing cases of acquisitions among key players can support the market in the near future, long-term benefits are likely to be earned. The rise in importance of cellular therapies can support the growth of the market through the analysis period.
Request Sample Copy: https://www.marketresearchfuture.com/sample_request/8102
Regional Analysis
The regional analysis of the global CAR T cell therapy market is analysed across Europe, APAC, MEA, North America, and the Rest of the World (RoW).
In North America, the US can secure the highest share of the regional CAR T cell therapy market through the analysis period. The rise in cases of cancer throughout the country. In Europe, CAR T-cell therapy market can thrive in the analysis period. The rise in occurrences of hematologic cancer, such as; lymphoma, leukemia, and multiple myeloma in the region is creating the need for immunotherapy that can favor the market in the assessment period. In Europe, the CAR T cell therapy market can acquire about 9.15% share of the world CAR T cell therapy market. The UK, following France can win high profits for the market. In APAC, China and India can thrive at a significant growth pace across APAC market in the study period. The rapid rise of the healthcare infrastructure and escalation of the disposable income can favor the regional market through the analysis period. The CAR T Cell therapy in the Middle East and Africa region can exhibit steady rise as healthcare access is limited and their affordability among the population is less.
Browse Complete Report: https://www.marketresearchfuture.com/reports/car-t-cell-therapy-market-8102
Key Players
Novartis AG (Switzerland), Sorrento Therapeutics (US), Kite Pharma (US), Juno Therapeutics (US), CARsgen Therapeutics (China), Pfizer, Inc. (US), Cellectis (France), Legend Biotech (US), Autolus Therapeutics PLC (UK), and Mustang Bio (US) among others are some reputed companies in the CAR T cell therapy market that are recognized by MRFR.
Global peripheral nerve stimulators market 2018-2027: Market Opportunities, Competitive Landscape, Segmentation, Analysis & Forecast
Market Highlights
Global peripheral nerve stimulators market expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 750.36 million in 2018 and is projected to grow at a CAGR of 7.7% over the forecast period. Peripheral Nerve Stimulators is expected to grow at a significant growth rate. The major factors influencing the growth of the market include; rising economic growth, increasing geriatric devices, increasing growth in technological advancement in the field of medical devices, rising neurological disorders, rising incidence of chronic health problems, and others.
Segmentation
The global peripheral nerve stimulators market has been segmented into product, and end user.
Based on product, the market is segmented into transcutaneous and implantable.
Based on end user, the peripheral nerve stimulators market is segmented into hospitals clinics, ambulatory centers, specialty center, and others.
Access Report Details @ https://www.marketresearchfuture.com/reports/peripheral-nerve-stimulators-market-8056
Key Players
Some of the major players operating in the global peripheral nerve stimulators market are B. Braun Melsungen AG, NeuroSigma, Inc, NeuroMetrix, Inc., Avanos Pain Management, Enteromedics, ElectroCore, Inc., Vygon SA, Boston Scientific Corporation, Medline Industries, Inc SPR Therapeutics LLC, Stimwave LLC., SUNMED INC., and others.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/8056
Regional Analysis
Geographically the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East Africa.
Geographically, The Americas led the market and accounted for the largest share of the peripheral nerve stimulators market in 2017 owing to the increasing prevalence of neurological diseases, aging population, and rising expenses in research and development by healthcare bodies and government. For instance, in 2017, according to the National SCI Statistical Center, around 288,000 people suffering from spinal cord injury in the US, whereas, 17,700 new spinal cord injury cases are estimated per year. Moreover, the increasing neurological disease would support regional market growth. Europe is expected to hold the second largest position in the global peripheral nerve stimulators market.
Asia-Pacific is the fastest growing peripheral nerve stimulators market owing to the huge patient pool of neurological diseases and government initiatives of healthcare reforms. According to Alzheimer’s Disease International, around 23 million people were affected by dementia in the Asia-Pacific region in 2015 and is projected to reach 71.0 million by 2050. The Middle East and Africa market for peripheral nerve stimulator is expected to grow at a steady.
global preclinical CRO market Segmentation, Dynamics, Market Size, Supply & Demand, Competition & Companies, Drivers, Restraints and Technology
Market Synopsis
According to Market Research Future (MRFR), the global preclinical CRO market is expected to acquire a market value of USD 5,234.7 while expanding at a CAGR of 8.14% by 2024.
The increasing demand to cut down RD costs is expected to be a significant factor that can drive the preclinical CRO market during the forecast period. The growing dependence of companies on outsourcing for drug development is anticipated to strengthen the trade in the forthcoming period. The technological advancement and the innovation of products are likely to grow the demand for preclinical services that can promote the industry in the assessment tenure. In addition, the tremendous expansion of pharmaceutical and biopharmaceutical sectors are anticipated to surge the need for CRO that may develop the trade during the projection period.
On the flip side, the lack of standardization of regulatory policies is expected to impede the clinical preliminaries’ demand during the review period. However, CROs’ improved efficiency is anticipated to counter the impeding factor that can aid in augmenting the preclinical CRO market.
Market Segmentation
The segmental analysis of the global preclinical CRO market is done by the application, services, and end-user.
The application-based segments of the global preclinical CRO market are Oncology, Diabetes, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Infectious Diseases, Immunological Disorders, Respiratory Diseases, and others.
The services-based segments of the global preclinical CRO market are bioanalysis bioanalysis, toxicology testing, drug metabolism, pharmacokinetics (DMPK) studies, etc. The toxicology testing segment is anticipated to lead the market during the review period. The segment is predicted to acquire the market value of USD 2,476.28 million by 2024. On the other hand, the bioanalysis and drug metabolism and pharmacokinetics (DMPK) segmented in likely to acquire the highest CAGR i.e., 8.96%, from 2019 to 2024.
The end-user based segments of the global preclinical CRO market are Medical Device Companies, Pharmaceutical and Biopharmaceutical Industries, and Academic Institutes.
Request Free Sample: https://www.marketresearchfuture.com/sample_request/7274
Regional Analysis
Based on the region, the global preclinical CRO market is segmented into North America, Europe, Asia-Pacific, and the Middle East Africa.
According to MRFR, the Americas is expected to dominate the market while expanding at a CAGR of 7.49% during the review period. The region is anticipated to dominate owing to the growing demand for drugs in the preclinical phase. The increasing outsourcing of non-core functions is likely to be another potential factor that can underpin the expansion of the regional market. Furthermore, the benefit to the contractor and the client is projected to fuel the demand for CROs that can aid in trade expansion.
APAC region is anticipated to exhibit the highest CAGR of 9.44% during the review period from 2019 to 2024. The regional market is predicted to augment owing to the growing demand for testing new drugs and chemicals. The expansion of pharmaceuticals is likely to play a salient cause in propelling the industry in the region.
Europe is anticipated to acquire a market value of more than USD 1,670.19 million by 2024. The increasing outsourcing activities in the region and availability of expertise are expected to drive the regional market during the review period.
MEA is anticipated to acquire the least market share during the forecast period. The region is likely to lag due to the sluggish development of countries situated.
Browse Complete Report: https://www.marketresearchfuture.com/reports/preclinical-cro-market-7274
Key Players
Eminent players of the global preclinical CRO market are PAREXEL International Corporation (US), IQVIA (US), Envigo (US), Eurofins Scientific (Luxembourg), Charles River (US), ICON PLC (Dublin), Medpace (US), PRA Health Sciences (US), and Laboratory Corporation of America Holdings (US).
Aesthetics Market 2027: Growth Opportunities, Segmentation, Competitive Landscape and Regional Analysis
Market Overview
MRFR (Market Research Future) anticipates that the Aesthetics Market could reach USD 12,175.1 MN by 2027-end.
Growth Boosters and Deterrents
Rising urge to remain and look young as well as fit among people has bolstered the need and demand for aesthetic treatments, with the trend emerging rapidly in developing nations. Aesthetic procedures including nose reshaping, Botox injections and liposuction are sparking the interest of consumers in South Korea and India. The aesthetics market is densely concentrated with a number of business giants that are involved in competitive and strategic rivalry to capture a higher position. This has resulted in an intensely competitive ambience in the global medical aesthetic industry.
The mounting preference for non-invasive and minimally invasive aesthetic procedures, geriatric pool emerging as a key end-user and the soaring awareness among the public about the latest cosmetic procedures are expected to benefit the aesthetics industry. The soaring number of options of technically innovative and user-friendly devices combined with the surging popularity of aesthetic treatment among the men population also seems to be working in favor of the global market.
Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/3136
Market Segmentation
Procedures and end-user are the top segments considered in the report, in order to present an exhaustive layout of the global market for aesthetics.
The major procedures discussed in the market study are nonsurgical aesthetic procedures as well as surgical aesthetic procedures. Mounting preference for non-invasive medical aesthetic procedures has been favorable for the nonsurgical aesthetic procedure segment. Non-surgical procedures witness substantial demand as these provide an array of benefits, including lower downtime, zero scar, no need for hospitalization, lesser treatment cost and reduced risks compared to surgical procedures.
The key market end users include salons spas, dermatology clinics cosmetic centers as well as hospitals clinics. Salons spas could be the fastest progressing segment in the following years, in view of the soaring number of medical spas around the globe along with the extensive use of technologically developed equipment devices. The burgeoning pool of skilled professionals and trained staff conducting aesthetic procedures in spas and salons gives further boost to the segment.
Regional Insight
Geographically, the aesthetics market has been split into Europe, the Americas, the Middle East Africa or MEA and Asia Pacific or APAC.
The American market has been split into North America and Latin America, while the North American market is further segmented into the US and Canada. The Americas has been the market leader since 2019 and should continue to retain its leadership throughout the assessment timeline. The presence of a highly established healthcare industry with a modern infrastructure and the rising burden of various types of skin disorders among consumers are key growth boosters in the regional market. Moreover, the growing popularity of advanced cosmetic procedures coupled with the large pool of skilled and board-certified surgeons add to the market value.
The aesthetics market in Europe has been considered for Western Europe and Eastern Europe. The Western European market for medical aesthetics consists of highly developed countries like France, Germany, Italy, the UK and Spain, which have well-defined healthcare infrastructures. The European market’s growth is backed by the supportive government, frequent research and development activities and the focus of the companies on business expansion.
The APAC market for aesthetics is headed by India, Japan, China, Australia, and South Korea. Asia Pacific could experience the fastest growth in the following years, in view of the expanding pool of skilled cosmetic professionals, availability of modern techniques as well as lower priced treatment options that attract a high number of customers. China along with India, accommodates an extensive population pool of individuals aged between 30 and 65 years. Also, the escalating disposable income per person along with the burgeoning pool of employed women that demand effective aesthetic procedures also strengthen the market’s hold in the region.
Browse Complete Toc :https://www.marketresearchfuture.com/reports/aesthetics-market-3136
Top Firms
Endocare, SkinCeuticals, Obagi Medical, Dermalogica, Neostrata, Clarins, Clinique, ZO Skin Health, Inc., La Roche-Posay, Medik8, Teoxane, Biore, Alumier MD, Kiehl’s, IS Clinical, Swisscode, Elemis Ltd, PCA Skin, Lancome, Skin Medica are the top market contenders listed in the report.
Latest Developments
January 2021
Allergan Aesthetics has formed an agreement with Cypris Medical, a renowned medical aesthetics device firm located in Chicago. Following a clinical trial scheduled in 2021, Allergan Aesthetics is expected to have the option of acquiring Cypris Medical, which includes the company’s Xact aesthetic device. The clinical trial will aim at analyzing the effectiveness as well as safety of Xact, for the treatment of midface descent and neck lifts. As an alternative to scalpel, Xact helps lift and suture the superficial muscular aponeurotic system and is minimally invasive.
global cystic fibrosis market Analysis, Growth Factors, Development Trends and Forecast to 2027
Overview
The global cystic fibrosis market, during the forecast period 2013 to 2025, will register growth at a CAGR of 13.5%. The market for cystic fibrosis is set to reach US$12,943.1 million by 2025. As per cystic fibrosis market analysts, the global market is anticipated to witness growth owing to the factors such as growing innovation to cure the disease as well as the availability of personalized drug therapy. However, the cystic fibrosis market will face challenges and restraints due to limited opportunities and the presence of limited revenue opportunities during the forecast period 2013 to 2025.
Molecular prosthetics to cure cystic fibrosis in the cystic fibrosis market is set to play a key role in determining the growth potential during 2013 to 2025 years. Analysts have also studied the cystic fibrosis market to understand potential threats and challenges the cystic fibrosis market companies could face. Although the cystic fibrosis market is poised to grow at a fast pace across treatment method segments, factors such as introduction of generic drugs could slow down the cystic fibrosis market’s growth worldwide.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/1825
Market Segmentation
The cystic fibrosis market has been segmented into treatment method. Based on the segment which is treatment method, the market is categorized on the basis of medication, devices, and others.
The global cystic fibrosis market research report covers all the aspects of the cystic fibrosis market based on the segmental analysis of these treatment method segments. Analysts have also studied the global cystic fibrosis market’s regional markets spread across many continents and countries. The treatment method segments along with their sub-segments have been analyzed and companies functioning in the cystic fibrosis market across these segments are profiled and analyzed based on input and feedback from cystic fibrosis market based decision makers as well as primary and secondary sources. The cystic fibrosis market research report presents analysis based information for companies functioning in the cystic fibrosis market.
Regional Overview
The introduction of generic drugs and patient expiration may hinder the cystic fibrosis market growth. The market research report suggests that companies in the cystic fibrosis market could be supported by the rising awareness about the disease across the globe as well as the increasing R&D investments made by the government during the forecast period. The cystic fibrosis market is set to register growth at a high CAGR owing to these key factors. The cystic fibrosis market is spread across North America, Europe, Asia-Pacific, and other parts of the world. The global cystic fibrosis market research report reveals that APAC, North America, and Europe regional cystic fibrosis markets will dominate the global market for cystic fibrosis during the forecast period 2013 to 2025. As per cystic fibrosis market analysts, the market is set to witness tremendous growth across medication and devices segments in North America which covers cystic fibrosis markets across the United States, Canada, Mexico and several other regional markets. Companies active in the cystic fibrosis market are also analyzed and studied in the cystic fibrosis market research report.
The cystic fibrosis market for Europe covers smaller market segments of Germany, Italy, France, and the United Kingdom. Additionally, the cystic fibrosis market research report covers the Asia-Pacific region covering cystic fibrosis markets from India, China, Japan, Australia, and others. The cystic fibrosis market is also spread across the rest of the world. The cystic fibrosis market report covers all such regions including the Middle East, Africa, Brazil, and others.
Competitive Landscape
Cystic fibrosis has seen increased demand over the years, due to development of pharmaceuticals and biotechnological sectors and the on-going development in the pharmaceuticals sector. Companies functioning in the global cystic fibrosis market are also being challenged due to the increasing monitoring from the government and unfavorable policies. Mergers and acquisitions by cystic fibrosis market companies are anticipated to help the market during the forecast period 2013 to 2025. As the cystic fibrosis market is set to register a high CAGR of 13.5% and is also anticipated to reach a US$12,943.1 million by 2025, the report highlights key areas companies need to focus on. The report suggests that the cystic fibrosis market will see a healthy growth in the long run till 2025. Based on SWOT analysis and cystic fibrosis market’s analysis based on Porters’ Five Force Model presented in the cystic fibrosis market report. Mergers and acquisitions by cystic fibrosis market companies are anticipated to help the market during the forecast period 2013 to 2025.
Access Complete Report @ https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825
Industry News
Roche and its South San Francisco-based affiliate Genentech are, in a sense, going back to their origins. The Swiss pharma behemoth purchased a portfolio of new cystic fibrosis treatments, including one that has the ability to cure all cystic fibrosis patients. Enterprise Therapeutics, based in England, sold the properties to Roche. Among the novel potentiators in the portfolio is, which has recently begun Phase I trials. The portfolio will be handled by Genentech, which received FDA clearance for Pulmozyme as a treatment for mild to severe cystic fibrosis in 1993.
global nuclear imaging devices market Size: Development, Growth, Trends, Demand, Analysis and Forecast 2027
Market Highlights
The global nuclear imaging devices market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 2490 million in 2018 and is projected to register a CAGR of 5.2% over the forecast period.
The increasing prevalence of cardiovascular disorders is one of the key factors driving the nuclear imaging devices market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.
Various other factors such as the advancements in radiotracers, acceptance of nuclear imaging devices in ambulatory settings, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on diagnostic imaging centers are also expected to propel the growth of the market.
However, the high cost of the nuclear imaging device, shorter half-life of radiopharmaceuticals can hamper market growth over the forecast period.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/8014
Segmentation
The global nuclear imaging devices market is segmented based on technology, application, end user, and region.
The global market for nuclear imaging devices, by technology, is segmented into positron emission tomography (PET), single photon emission computed tomography (SPECT), and planar scintigraphy. The single-photon-emission computed tomography (SPECT) are further classified as hybrid SPECT systems and standalone SPECT systems.
Based on application, the market is segmented into oncology, cardiology, neurology, and others.
Based on end user, the market is segmented into hospitals, diagnostic imaging centers, and others.
The diagnostic imaging centers segment is expected to witness the fastest growth over the forecast period due to rising adoption of nuclear imaging in diagnostic centers.
Key Players
Some of the key players in the global nuclear imaging devices market are Philips Healthcare, Digirad Corporation, Neusoft Medical Systems Co., Ltd., Progenics Pharmaceuticals Inc., Cannon Inc., Surgiceye GmbH, CMR Naviscan, Mediso Medical Imaging Systems Ltd., Agfa-Gevaert Group, General Electric Company, DDD-Diagnostic A/S, Spectrum Dynamics Medical, FMI Medical Systems, Inc., Segamicorp, and others.
Access Report Details @ https://www.marketresearchfuture.com/reports/nuclear-imaging-devices-market-8014
Regional Analysis
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The nuclear imaging devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European nuclear imaging devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The nuclear imaging devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nuclear imaging devices market in the Middle East Africa has been segmented into the Middle East and Africa.
Global Automatic Pill Dispenser Market to Expand with Significant CAGR During 2027
Market Highlights
The Global Automatic Pill Dispenser Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 1,700 million in 2018 and is projected to register a CAGR of 7.3% over the forecast period.
The increasing prevalence of cardiovascular disorders and growing older population are the key factors driving the automatic pill dispenser market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.
Various other factors such as the advancements in automatic pill dispenser, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on home care centers are also expected to propel the growth of the market.
However, the high cost of the system can hamper market growth over the forecast period.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/8008
Segmentation
The global automatic pill dispenser market is segmented based on type, end user, and region.
The global market for automatic pill dispenser, by type, is segmented into a centralized, automated dispensing system, and decentralized the automated dispensing system. The centralized, automated dispensing system is further classified into robotic automated dispensing systems, and carousels. Furthermore, the decentralized automated dispensing system is classified into a pharmacy-based automated dispensing system, ward-based automated dispensing system, and automated unit dose dispensing system.
Based on end user, the market is segmented into hospital pharmacy, retail pharmacy, and home healthcare.
The centralized, automated dispensing system segment is expected to witness the fastest growth over the forecast period due to increasing adoption in various hospitals as well as other healthcare facilities.
Key Players
Some of the key players in the global automatic pill dispenser market are Baxter International Inc, Becton, Dickinson and Company, Cerner Corporation, Capsa Healthcare, McKesson Corporation, Omnicell Inc., ScriptPro LLC, Swisslog Holdings AG, Yuyama Co.Ltd. Talyst, Inc., and others
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/automatic-pill-dispenser-market-8008
Regional Analysis
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The automatic pill dispenser market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European automatic pill dispenser market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The automatic pill dispenser market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The automatic pill dispenser market in the Middle East Africa has been segmented into the Middle East and Africa.
global medical vacuum systems market Industry Trends and Developments 2019 – 2027
Market Highlights
The global medical vacuum systems market held a market value of USD 1,030.5 million in 2017 and is projected to grow at a CAGR of 7.1% over the forecast period. Vacuum system maintains the pressure inside a chamber under the value of the atmospheric pressure. A medical vacuum system provides a safe, adequate flow of vacuum, and the required pressure to be used in the healthcare facilities such as operating theaters (OTs), intensive care centers, and emergency and respirology/general medicine units. These systems create a suction system to eliminate unnecessary fluids or gases from hospital or laboratory working areas. Factors facilitating the market growth are worldwide growing geriatric population, increasing number of surgical and diagnostic imaging procedures, technological developments in vacuum equipment, and the presence of regulatory frameworks mandating the use of vacuum systems in the healthcare settings coupled with rising adoption of medical vacuum systems. For instance, the World Health Organization (WHO) reported that the worldwide population aged 60 years and above was 962.0 million in 2017, which is projected to increase to over 2.0 billion by 2050 and further would reach to 3.1 billion by 2100. On the flip side, the high cost of vacuum systems and heavy structure of vacuum equipment are anticipated to hinder the market growth during the forecast period.
Request Free Sample:
https://www.marketresearchfuture.com/sample_request/7569
Regional Analysis
The global medical vacuum systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. On a regional basis, the Americas is expected to command the global medical vacuum systems market. This is attributed to the presence of key market participants (Olympus Corporation, ZOLL Medical Corporation, Ohio Medical Corporation, Precision Medical, Inc.) and sophisticated healthcare infrastructure, implementation of regulatory norms for cleanroom maintenance, manufacturing guidelines, and surgical protocols, rising number of target surgical procedures, increasing end user base, and growth in healthcare expenditure in the US and Canada.
Burgeoning medical device sector in the UK, Germany, and France and the presence of various medical vacuum equipment associations such as European Industrial Gases Association (EIGA), Association of Vacuum Equipment Manufacturers (AVEM), and European Association of Manufacturers of Compressors, Vacuum Pumps are expected to support the second-largest position of Europe in the global market.
Asia-Pacific is likely to witness the fastest market growth during the forecast period due to growing aging population coupled with the rising burden of chronic diseases, increasing per capita spending on healthcare, and rising adoption of medical vacuum equipment in healthcare facilities. For instance, as per data published by the World Health Organization (WHO), in 2016, 40.5 million (71% of total deaths), were happened due to non-communicable diseases (NCDs) worldwide and more than three quarters of NCD deaths — 31.5 million occurred in low- and middle-income countries with around 46% of deaths occurring below the age of 70 in these countries.
The Middle East & Africa has the least share of the global medical vacuum systems market. In addition, the major market share of the region would be held by the Middle East region due to the budding medical device industry and developing healthcare infrastructure in the Gulf Cooperation Council (GCC) countries.
Browse Complete Report Details @ https://www.marketresearchfuture.com/reports/medical-vacuum-systems-market-7569
Segmentation
The global medical vacuum systems market has been segmented into product, technology, application, end user, and region.
By product, the market has been segmented into standalone vacuum systems, centralized vacuum systems, portable and compact vacuum systems, and accessories.
On the basis of technology, the market has been divided into dry claw vacuum pump technology, dry rotary vane technology, oil-sealed rotary vane technology, oil-sealed liquid ring technology, and water-sealed liquid ring technology.
Based on application, the market has been categorized into therapeutic applications, diagnostic, research, and pharmaceutical, and biotechnology manufacturing. The therapeutic applications segment is further categorized into wound care, dental, anesthesiology, and gynecology.
By end user, the market has been categorized into hospitals, clinics, and surgery centers, pharmaceutical and biotechnology industries, diagnostic laboratories, and research and academic institutes.
Key Players
Some of the spearheading players in the global medical vacuum systems market are Olympus Corporation, Atlas Copco AB, ZOLL Medical Corporation, Integra Biosciences AG, Ohio Medical Corporation, Precision Medical, Inc., Drägerwerk AG & Co. KGaA, Busch Holding GmbH, Medela Holding AG, BeaconMedæs, Gardner Denver, Inc., DEKKER Vacuum Technologies, Inc., Allied Healthcare Products, Inc., and Air Techniques, Inc.
EHR-EMR Market 2027: Growth Opportunities, Segmentation, Competitive Landscape and Regional Analysis
Market Portrayal
The latest report has been published to Market Research Future’s offering in this COVID 19 pandemic that states, the Global and US EHR-EMR Market 2020 might strike growth at a percent of 5.82 from 2015 through 2027. With this, this year also, the market would gain revenue of USD 42,427.27 million.
US EHR-EMR Market Boomers & Decliners
The development of healthcare IT and the enormous potential of the sector in combining data as well its capability are to radically surge the efficiency has affected the US EHR/EMR market to a great extent. EHRs and EMRs facilitate medical errors that are often faced at the time of diagnosis and treatment procedure. This occurs owing to a lack of awareness on the part of medical professionals concerning medical history and the therapeutic guidelines specific to the patient. On this, it is reportedly stated that the clinical decisions made using the assistance of EHRs have augmented the efficiency of care and the market as well.
The clinical benefits are essential in its positive influence on the global EHR/EMR market. Growing government support of the EHRs has also been a vital encouraging factor for the adoption of both EHRs and EMRs for subsequent growth in the market on the global level. In a case of point, NMS has employed the Integrated Digital Care Fund (IDCF) to support the shift from paper-based records to digital care records. These types of encouraging and supportive government initiatives are anticipated to induce market growth over the assessment period.
Request Free Sample: https://www.marketresearchfuture.com/sample_request/819
Segment Review
The global and US EHR-EMR market is further studied over various segments of components, applications, mode of delivery, and end-user.
By the segment of components, the market has included services & consulting software and hardware.
By the segment of the application, the market has included specialty-based and general applications.
By the segment of the mode of delivery, the market has included an on-premise model and cloud-based.
By the segment of end-user, the market has included forensic science laboratories and hospitals.
Regional Framework
Regionally, the US was the leading global EHR market in the year 2018 (with a 64% market share at $14.6B), but its growth is now projected to rise more as new verticals, functionality, and international markets have become a key focus for leading vendors. US vendors grabbed the position of being seven of the top 10 largest EHR vendors, with the other three from the second-largest market in Japan. Therefore, the Americas is likely to lead the global & US EHR-EMR market owing to the escalating adoption of healthcare IT and encouraging incentive programs in the assessment period. The Americas secured the largest market share of USD 11,763.33 million in the year 2017 and is probable to govern the global & US EHR-EMR market by reaching USD 21,307.35 million by 2027 at 5.82% CAGR. It is also owing to the incidence of many key players and technologically advanced healthcare infrastructure in this region.
The government in Europe gradually supported the adoption of electronic health record EHR-EMR facilitates. Such an attempt has made Europe the second largest market share in the year 2017 and will be leading in the forecast period
Asia-Pacific is also predicted to be the fastest-growing market in the future timeframe. In the Asia-Pacific EHR-EMR market, Japan commands the largest share. In China, the market is prejudiced by the factor of rising geriatric population and extensive use of healthcare IT. Emerging economies, such as India, Australia, Singapore, and China, are the most lucrative markets owing to the rising geriatric population, as well as rising the patient pool, and improving healthcare facilities.
Browse Complete Report: https://www.marketresearchfuture.com/reports/ehr-emr-market-819
Top Vendors
The core vendors in the global & US EHR-EMR market are Allscripts Healthcare Solutions, GE Healthcare, Advanced Data Systems Corporation, AdvancedMD Inc., Epic Systems, Meddbase (Medical Management Systems Ltd), Agastha, Inc., Koninklijke Philips NV, and Medical Information Technology, Inc. (MEDITECH).
